Publications & Posters
Scholarly publications
Spinal Muscular Atrophy
Apitegromab
February 2024
Neurology
Safety and Efficacy of Apitegromab in Patients With Spinal Muscular Atrophy Types 2 and 3
Cardiometabolic Disease
SRK-439
February 2024
Keystone Symposia: Obesity Causes and Consequences Conference
SRK-439, a Selective Anti-Pro and Latent Myostatin Antibody, Maintains Lean Mass and Enhances Fat Mass Loss in Models of Pharmacologically Induced Weight Loss
Immuno-Oncology
SRK-181
November 2023
Society for Immunotherapy of Cancer 2023
Safety, Efficacy, and Biomarker Results of SRK-181, a Latent TGFβ1 Inhibitor, in Anti‑PD-1 Resistant Metastatic ccRCC Patients
Immuno-Oncology
SRK-181
November 2023
Society for Immunotherapy of Cancer 2023
Establishing Proof of Mechanism in Patients: Preliminary Biomarker Data of SRK-181 (a latent Tβ1 inhibitor) from DRAGON Study
Spinal Muscular Atrophy
Apitegromab
October 2023
World Muscle Society 2023 Meeting
Effect of apitegromab on PEDI-CAT and PROMIS Fatigue questionnaire at 36 months in patients with spinal muscular atrophy
Spinal Muscular Atrophy
Apitegromab
October 2023
World Muscle Society 2023 Meeting
